Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
2006 1
2007 1
2008 2
2009 3
2010 3
2011 2
2012 37
2013 61
2014 57
2015 84
2016 89
2017 85
2018 112
2019 107
2020 101
2021 114
2022 111
2023 99
2024 97
2025 116
2026 71

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,143 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.
He W, Zhang Y, Huang G, Tian Y, Sun Q, Liu X. He W, et al. Low Urin Tract Symptoms. 2023 May;15(3):80-88. doi: 10.1111/luts.12475. Epub 2023 Mar 2. Low Urin Tract Symptoms. 2023. PMID: 36863312
Vibegron was more efficacious than mirabegron in reducing mean voided volume/micturition (95% CI [5.15, 14.98]). Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasophar …
Vibegron was more efficacious than mirabegron in reducing mean voided volume/micturition (95% CI [5.15, 14.98]). Safety outcomes for …
Activation of beta3-adrenergic receptor by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue.
Zhang ZB, Cheng YW, Xu L, Li JQ, Pan X, Zhu M, Chen XH, Sun AJ, Lin JR, Gao PJ. Zhang ZB, et al. Cardiovasc Res. 2024 Dec 31;120(17):2307-2319. doi: 10.1093/cvr/cvae213. Cardiovasc Res. 2024. PMID: 39288197 Free article.
Moreover, activation of beta3-AR by mirabegron significantly prevented AngII-induced AD/AA formation in mice. RNA-sequencing analysis of adipocytes from PVAT revealed a notable increase of the lymphangiogenic factor, vascular endothelial growth factor C (VEGF-C), in mir …
Moreover, activation of beta3-AR by mirabegron significantly prevented AngII-induced AD/AA formation in mice. RNA-sequencing analysis …
Mirabegron: Pediatric First Approval.
Keam SJ. Keam SJ. Paediatr Drugs. 2021 Jul;23(4):411-415. doi: 10.1007/s40272-021-00452-4. Paediatr Drugs. 2021. PMID: 34056686 Review.

In addition to mirabegron ER tablets (which can be used in pediatric patients weighing 35 kg), mirabegron is available as an ER oral suspension (MYRBETRIQ( ) Granules) for pediatric patients; in those weighing < 35 kg, only the ER oral suspension formulation sh

…
In addition to mirabegron ER tablets (which can be used in pediatric patients weighing 35 kg), mirabegron is available as an …
Mirabegron.
Goulooze SC, Cohen AF, Rissmann R. Goulooze SC, et al. Br J Clin Pharmacol. 2015 Oct;80(4):762-4. doi: 10.1111/bcp.12647. Epub 2015 Jun 5. Br J Clin Pharmacol. 2015. PMID: 25819590 Free PMC article.
Mirabegron is used for the treatment of symptoms associated with overactive bladder syndrome. ...
Mirabegron is used for the treatment of symptoms associated with overactive bladder syndrome. ...
Mirabegron bei Kindern mit Spina bifida.
[No authors listed] [No authors listed] Aktuelle Urol. 2020 Aug;51(4):320-322. doi: 10.1055/a-1019-5586. Epub 2020 Jul 29. Aktuelle Urol. 2020. PMID: 32726843 German. No abstract available.
Posterior Tibial Nerve Stimulation With versus Without Mirabegron: A Randomized Controlled Trial.
Stanley RF, Meyer I, Blanchard CT, Richter HE. Stanley RF, et al. Int Urogynecol J. 2024 Aug;35(8):1709-1717. doi: 10.1007/s00192-024-05835-y. Epub 2024 Aug 5. Int Urogynecol J. 2024. PMID: 39101958 Free PMC article. Clinical Trial.
INTRODUCTION AND HYPOTHESIS: To compare change in urgency urinary incontinence episodes (UUIEs) in women undergoing posterior tibial nerve stimulation (PTNS) plus mirabegron versus PTNS plus placebo for the treatment of refractory urgency urinary incontinence (UUI). ...Par …
INTRODUCTION AND HYPOTHESIS: To compare change in urgency urinary incontinence episodes (UUIEs) in women undergoing posterior tibial nerve s …
Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Wagg A, et al. Curr Med Res Opin. 2016;32(4):621-38. doi: 10.1185/03007995.2016.1149806. Epub 2016 Feb 17. Curr Med Res Opin. 2016. PMID: 26828974
RESULTS: Anticholinergic adverse events (AEs) including dry mouth and constipation were more frequent with antimuscarinics versus mirabegron. In patients aged 65 years, dry mouth occurred with a six-fold higher incidence with tolterodine extended-release (ER) 4 mg than wi …
RESULTS: Anticholinergic adverse events (AEs) including dry mouth and constipation were more frequent with antimuscarinics versus mirabeg …
Mirabegron: a safety review.
Tyagi P, Tyagi V, Chancellor M. Tyagi P, et al. Expert Opin Drug Saf. 2011 Mar;10(2):287-94. doi: 10.1517/14740338.2011.542146. Epub 2010 Dec 9. Expert Opin Drug Saf. 2011. PMID: 21142693 Review.
INTRODUCTION: Mirabegron is being developed as a new treatment for the management of overactive bladder (OAB). ...The most commonly reported toxic effects of mirabegron are gastrointestinal adverse events and headache....
INTRODUCTION: Mirabegron is being developed as a new treatment for the management of overactive bladder (OAB). ...The most commonly r …
Mirabegron nighttime versus daytime dosing for women with overactive bladder syndrome: a randomized controlled trial.
Hsiao SM. Hsiao SM. Sci Rep. 2025 Aug 21;15(1):30687. doi: 10.1038/s41598-025-15780-5. Sci Rep. 2025. PMID: 40841399 Free PMC article. Clinical Trial.
The effect of nighttime dosing versus daytime dosing of mirabegron is undetermined. Thus, this study aimed to clarify the effect of nighttime versus daytime mirabegron dosing. Between August 2017 and August 2023, all women with overactive bladder syndrome were rando …
The effect of nighttime dosing versus daytime dosing of mirabegron is undetermined. Thus, this study aimed to clarify the effect of n …
Pharmacotherapy for overactive bladder syndrome and the risk of incident dementia.
Sheyn D, Murphy J, Mahajan A, Bretschneider CE, Scott L, Rhodes S, Hijaz A, Gupta A. Sheyn D, et al. World J Urol. 2025 Apr 4;43(1):212. doi: 10.1007/s00345-025-05595-4. World J Urol. 2025. PMID: 40183931
Patients who were diagnosed with OAB who were prescribed Mirabegron, Oxybutynin, Tolterodine, Darifenacin, Trospium, Fesoterodine, or Solifenacin after 1/1/2012 were identified. ...CONCLUSIONS: Most anticholinergic medications and mirabegron are associated with an i …
Patients who were diagnosed with OAB who were prescribed Mirabegron, Oxybutynin, Tolterodine, Darifenacin, Trospium, Fesoterodine, or …
1,143 results